Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $55.29 Consensus PT from Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $55.2857.

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wells Fargo & Company raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 20,129 shares of the stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the completion of the sale, the director owned 12,546 shares of the company’s stock, valued at $520,784.46. This trade represents a 61.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the sale, the chief operating officer owned 16,666 shares in the company, valued at $692,638.96. This represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 80,782 shares of company stock worth $3,458,916 in the last 90 days. 53.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $267,000. Invesco Ltd. increased its position in shares of Kiniksa Pharmaceuticals International by 25.9% during the fourth quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock worth $1,334,000 after acquiring an additional 6,656 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Kiniksa Pharmaceuticals International by 7.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares in the last quarter. Empowered Funds LLC purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $51,000. Finally, XTX Topco Ltd purchased a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $291,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $45.78 on Monday. Kiniksa Pharmaceuticals International has a 1 year low of $18.25 and a 1 year high of $49.12. The firm has a 50 day moving average price of $43.83 and a 200 day moving average price of $40.67. The company has a market cap of $3.50 billion, a PE ratio of 61.86 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% compared to the same quarter last year. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.